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Aim: With the exception of ring chromosome 14 or translocations, interstitial deletions of the long arm of chromosome 
14 are very rare. All patients with these deletions share common phenotypic characteristics, primarily mild dysmorphia 
and developmental delay. Molecular karyotyping (array CGH) enabled the precise breakpoint determination and 
improved the analysis of genotype-phenotype correlations. 
Case presentation: In a 7-year-old girl, array CGH was performed due to developmental delay. The array CGH study 
showed 8.3Mb de novo interstitial deletion of the 14q31.3–q32.13 region. 
Conclusions: Comparison of our patient´s phenotype with previously reported chromosome 14q interstitial deletion 
cases confirmed the presence of common clinical features and highlights the utility of array CGH as a diagnostic tool in 
clarifying the developmental delay etiology. 
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Cytogenetic diagnostic has been highly 
improved/transformed through the implementation of 
new molecular technologies. Routine analysis of 
metaphase and prometaphase chromosomes using the 
GTG banding technique with a resolution of 400-500 
bands enables the detection of structural aberrations in 
the size of ≥5-10 Mb. Clearly, chromosome banding 
techniques continue to be widely used, although the 
resolution depends mostly on the chromosome length 
and the resolution limits of light microscopy. However, 
a great number of clinical phenotypes are caused by 
cryptical chromosome rearrangements that are less than 
3Mb in size, and as such represent microdeletions and 
microduplications that are impossible to detect by 
using the GTG banding technique. 
The application of high-resolution molecular 
techniques in research of developmental delay and the 
etiology of multiple congenital anomalies have led to 
exponential growth in discovering new microdeletion 
and microduplication syndromes. The most 
improvement in detecting genomic aberrations has 
been accomplished by using the molecular karyotyping 
technique (aCGH - Array-based comparative genomic 
hybridization), which enables whole genome screening 
for duplications and deletions of specific DNA 
sequences. Literature data confirms the importance of 
aCGH technique implementation in the evaluation of 
patients with developmental delay and congenital 
anomalies. Therefore, this method is recommended as 
the first genetic test in children and adults with 
undiagnosed clinical manifestations. The application of 
this method detects 14-20% of aberrations: 9-10% are 




This method is limited by the inability to detect 
balanced chromosomal abnormalities and low-level 
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mosaicism, but it detects copy number variations 
(CNV). CNVs are DNA segments, ranging in size from 
1 kilobase to a few megabases, causing genome 
imbalance. It appears that CNVs may be responsible 
for differences among people and evolution processes, 
but they can also affect clinical phenotype. The results 
of the aCGH analysis are classified into five categories: 
pathogenic, likely pathogenic, variation of uncertain 
significance (VUS) detected in one of the parents and 
VUS that has not been detected in parents, likely 
benign and benign. CNVs classified as likely benign 
and benign were not reported to the patients.
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Discovering VUS makes interpretation of the results a 
challenge. For a given VUS, it is not clear whether it is 
associated with clinical features because there is still 
insufficient knowledge about correlation between 
detected microduplications or microdeletions and their 
effect on the phenotype. In such cases it is important to 
search literature and databases to find patients with the 
same disorder in the chromosome region and clinical 
features. Only careful phenotype-genotype comparison 
can improve the interpretation of such results. Genetic 
counselling is necessary before and after testing, and 
patients with VUS need to be monitored and evaluated 
again for the status of discovered change.  
In our laboratory, the aCGH method is used to evaluate 
patients with apparently balanced chromosomal 
rearrangements and normal karyotype individuals with 





A 7-year-old Caucasian girl was referred to our 
Department of Genetics by a neuropediatrician due to 
developmental delay of uncertain origin. She was born 
at term after an uncomplicated pregnancy to healthy 
non-related parents. Their first child is a healthy girl 
and the family history is unremarkable. At birth, the 
patient's weight was 3100 g, length 50 cm and Apgar 
score 10/10. Evaluation due to developmental delay 
started at the age of 3. The clinical examination at 7 
years of age showed that her body weight was at the 
75th percentile, height at the 25th and head 
circumference at the 50th percentile. Dysmorphic 
features of the face were observed, bulbous nose, 
micrognathia, thin upper lip, low-seat ears and high-
arched palate without clefts. Developmental milestones 
were mildly delayed; she started walking at 20 months. 
No malformations of internal organs were discovered. 
Psychological evaluation showed mild cognitive delay 
with restricted language expression. During childhood 
she had frequent ear infections. Left-sided conductive 
loss of hearing was found on audiologic examination. 
She did not have any epileptic or non-epileptic events 
despite focally changed EEG, regularly monitored by a 
neuropediatrician. Classical cytogenetic analysis 
revealed a female karyotype 46,XX with a suspicion of 
14q terminal deletion  (Figure  1).  Cytogenetics  of 
peripheral  blood 
 




lymphocytes from both parents revealed normal 
karyotypes. Available FISH (Fluorescent In Situ 
Hybridization) - probe set (centromeric probe, whole 
chromosome 14 paint probe, and locus-specific probes 
14q11.2, 14q32, t(11;14) and sub-telomeric 14qter) 
was not informative. Thus, no conclusion could be 
drawn considering the presence of 14q terminal 
deletion. DNA was extracted from peripheral blood and 
analyzed using array-CGH (aCGH) on the platform 
SurePrint CGH 8x60K G3 ISCA (Agilent 
Technologies) and the CytoGenomics software. 
Molecular karyotype analysis revealed de novo 8.3 Mb 
interstitial deletion encompassing chromosomal region 
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Interstitial deletions at the long arm of chromosome 14 
are considered very rare. Only a limited number of 
cases with such a defect can be found in literature, with 
few of them partially including the region affected by 
deletion verified in our patient. The type and the 
severity of symptoms depend on the size and location 
of deletion. Table 1 summarizes the clinical 
presentation of our patient in relation to cases from 
literature. Phenotypic comparison reveals common 
clinical features. The neurodevelopmental features 
were quite consistent with some frequent and non-
specific dysmorphic signs including hypertelorism, 
bulbous nose with a depressed bridge, thin upper lip 
and low-set ears, while malformations of internal 
organs were not found. The mild phenotypic 
presentation may indicate that the deleted segment does 
not contain genes important for early organ 
development. Therefore, we could conclude that it 
would be difficult to recognize similar cases on the 
basis of clinical findings alone. 
 
 
Table 1. Presented patient phenotype correlated with patients 
described in literature (adjusted by ref. 4 and 5) 
CLINICAL 
FEATURE 








q31q32.3 q31.3q32.2 q31.3q32.13 
Mental 
retardation 
+ + + 
Microcephaly + + - 
Strabismus NR + - 
Rounded nose 
tip 
+ + + 
Long philtrum + + + 
Thin upper lip + + + 
Low set ears  + + + 
Rounded 
palate 
Uvula bifida Cleft palate 
High-arched 
palate 
Growth delay + - - 
Parent of 
origin 
not specified Pat De novo 
(+) present, (-) absent, Pat - paternal originate, de novo - a new 
deletion; NR – nor reported  
 
 
The deleted region contains 52 OMIM genes, including 
the following 15 morbid genes: ATXN3, CALM1, 
CCDC88C, FBLN5, GALC, GPR68, GSC, AAT 
(SERPINA1), SERPINA6, SLC24A4, SPATA7, TDP1, 
TRIP11, TTC8, ZC3H14. From these, pathogenic 
variants in some genes have been described in AD 
diseases or syndromes such as: spinocerebellar ataxia 
with axonal neuropathy (OMIM 607250), cutis laxa 
type I (OMIM 219100) and FBLN5 gene, Machado–
Joseph disease (OMIM 109150) and ATXN3 gene, 
Long QT syndrome 14 (OMIM 616247), Ventricular 
tachycardia, catecholaminergic polymorphic, 4 (OMIM 
614916) and CALM1 gene, Spinocerebellar ataxia 40 
(OMIM 616053) and CCDC88C, Corticosteroid-
binding globulin deficiency (OMIM 611489) and 
SERPINA6. The phenotype of the proband does not 
match conditions listed above. The AAT gene, also 
designated as PI (protease inhibitor), is located in the 
14q32.1 region. When deleted, it is associated with 
emphysema and liver insufficiency, thus pointing to the 
need for α1-AT blood level monitoring among deletion 
carriers.
6-9
 The size of the deleted region, the location 
of multiple genes in it, as well as the limited number of 
published clinical-genetic case series, makes genotype-
phenotype correlation difficult. Therefore, newly 
discovered and thoroughly genetically described 
disease carriers will contribute to the elucidation of the 
functional relevance of the aforementioned region.  
The implementation of aCGH is a practice-changing 
methodology improvement in the field of cytogenetic 
workup of patients with developmental delay with or 
without dysmorphic changes. Classical cytogenetics, 
with the GTG-banding technique, may lead to 
diagnosis in about 3% of such patients, excluding well-
defined syndromes (Down’s syndrome etc.). Molecular 
karyotyping may significantly increase efficacy in 
diagnosing the etiology of developmental delay. The 
presented case illustrates the greater ability of aCGH in 
defining etiopathogenetic background that could only 
be suspected, based on GTG-banding cytogenetic 
finding. Such approach profoundly improves genetic 
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